Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know

An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.

FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know

We haven't written up this one. Live Mint has the full story — the link below goes straight to it.

Read the original at livemint.com →

More in Health & Medicine

More from Tuesday 10 November →